People with a history of cognitively stimulating occupations during their 30s, 40s, 50s, and 60s had a lower risk of mild cognitive impairment and dementia after age 70.
Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
With funding from the Ultra-rare Gene-based Therapy Network, scientists at Columbia and the n-Lorem Foundation will create tailor-made gene-based therapies for people with rare forms of ALS.
A Mailman study of more than 1 million pregnancies in Finland reports that prenatal exposure to elevated levels of DDT is associated with an increased risk for autism.
A new clinical trial suggests that donepezil does not improve cognitive performance in people with mild cognitive impairment who also have clinical depression.
In one of the first studies of its kind, Columbia’s Philip De Jager shows how "big data" analyses may lead to new treatment strategies for Alzheimer's disease.
Scientists at Columbia University Vagelos College of Physicians and Surgeons present the most definitive evidence to date that the human brain makes new neurons throughout life.